CARDIFF ONCOLOGY, INC. Operating Lease, Impairment Loss
CARDIFF ONCOLOGY, INC. (CRDF) reported Operating Lease, Impairment Loss of $0 for the 9-month period ending 2021-09-30, per its 10-Q filed 2021-11-04.
Discontinued › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseImpairmentLoss · last filed 2021-11-04
- CARDIFF ONCOLOGY, INC. operating lease, impairment loss for the quarter ending 2021-09-30 was $0.00.
- CARDIFF ONCOLOGY, INC. operating lease, impairment loss for the quarter ending 2020-12-31 was $169.00.
- CARDIFF ONCOLOGY, INC. operating lease, impairment loss for the quarter ending 2020-09-30 was $0.00.
- CARDIFF ONCOLOGY, INC. operating lease, impairment loss for the quarter ending 2020-06-30 was $34.17K.
- CARDIFF ONCOLOGY, INC. operating lease, impairment loss for fiscal 2020 was $34.17K.
- CARDIFF ONCOLOGY, INC. operating lease, impairment loss for fiscal 2019 was $0.00.
| Period end | Operating Lease, Impairment Loss 3 month | Operating Lease, Impairment Loss 6 month | Operating Lease, Impairment Loss 6 month as first filed | Operating Lease, Impairment Loss 9 month | Operating Lease, Impairment Loss 9 month as first filed | Operating Lease, Impairment Loss 12 month |
|---|---|---|---|---|---|---|
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $0.00 10-Q · filed 2021-11-04 | ||||
| 2021-06-30 | $0.00 10-Q · filed 2021-08-05 | |||||
| 2020-12-31 | $169.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $169.00 derived: sum of 2 quarters · filed 2021-02-25 | $34.34K derived: sum of 3 quarters · filed 2021-02-25 | $34.17K 10-K · filed 2021-02-25 | ||
| 2020-09-30 | $0.00 10-Q · filed 2020-11-05 | $34.17K derived: sum of 2 quarters · filed 2020-11-05 | $34.00K 10-Q · filed 2021-11-04 | $34.17K 10-Q · filed 2020-11-05 | $34.00K derived: sum of 4 quarters · filed 2021-02-25 | |
| 2020-06-30 | $34.17K 10-Q · filed 2020-08-11 | $34.00K 10-Q · filed 2021-08-05 | $34.17K 10-Q · filed 2020-08-11 | $34.00K derived: sum of 3 quarters · filed 2021-02-25 | $34.00K derived: sum of 4 quarters · filed 2021-02-25 | |
| 2020-03-31 | -$169.00 derived: 10-K 12 month − 3 quarters · filed 2021-02-25 | -$169.00 derived: sum of 2 quarters · filed 2021-02-25 | -$169.00 derived: sum of 3 quarters · filed 2021-02-25 | |||
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $0.00 derived: sum of 2 quarters · filed 2021-02-25 | $0.00 10-K · filed 2021-02-25 | |||
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $0.00 10-Q · filed 2020-11-05 | ||||
| 2019-06-30 | $0.00 10-Q · filed 2020-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B |